Last reviewed · How we verify

Theradex — Portfolio Competitive Intelligence Brief

Theradex pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Addpharma Inc. · 1 shared drug class
  2. Air Force Military Medical University, China · 1 shared drug class
  3. Akeso · 1 shared drug class
  4. AmMax Bio, Inc. · 1 shared drug class
  5. Aronora, Inc. · 1 shared drug class
  6. Astellas Pharma Europe B.V. · 1 shared drug class
  7. Astellas Pharma Global Development, Inc. · 1 shared drug class
  8. AbbVie (prior sponsor, Abbott) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Theradex:

Cite this brief

Drug Landscape (2026). Theradex — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/theradex. Accessed 2026-05-13.

Related